Skip to main content
. 2014 Apr 29;14:33. doi: 10.1186/1471-2490-14-33

Table 1.

Characteristics of patients and the results of the log-rank test of prognostic factors

    Median (range) No. of patients No. of CRPC Median progression time (months)   No. of deaths Median survival time (months)  
Total
 
 
286
207
19
 
102
113
 
Age
 
73 (50–91)
 
 
 
 
 
 
 
 
≤75
 
179
132
19
 
69
85
 
 
≥76
 
107
75
18
n.s.
33
none
n.s.
T
T1
 
4
2
57
*(T2 vs. T3, T4)
0
all alive
 
 
T2
 
31
18
37
9
111
 
 
T3
 
162
114
19
60
83
 
 
T4
 
89
73
14
33
77
n.s.
N
N0
 
164
116
19
 
59
79
 
 
N1
 
122
91
19
n.s.
43
99
n.s.
M
M0
 
50
31
26
 
9
99
 
 
M1
 
236
176
18
n.s.
93
83
n.s.
Gleason score
6-8
 
181
83
21
*
63
115
 
 
9-10
 
105
124
14
39
85
n.s.
PSA at diagnosis
 
174 (5.7-21864)
 
 
 
 
 
 
 
 
<100
 
105
64
23
*(<100 vs. ≥500)
31
85
 
 
100-500
 
97
73
16
36
113
 
 
≥500
 
84
70
15
35
none
n.s.
Nadir PSA level
 
0.3 (0.001-650)
 
 
 
 
 
 
 
 
<0.2
 
122
71
38
**
26
115
***
 
0.2-4
 
112
86
13
44
62
 
≥4
 
52
50
8
32
25
Time from PADT to Nadir
 
9.45 (1–64)
 
 
 
 
 
 
 
 
≥12
 
114
74
35
**
23
113
***
 
6-12
 
83
62
13
39
79
 
<6
 
89
71
7
40
28
Time from PADT to CRPC
 
13 (1–97)
 
 
 
 
 
 
 
 
No CRPC
 
79
 
 
 
14
none
 
 
≥12
 
112
 
 
 
32
113
***
 
6-12
 
63
 
 
 
34
35
 
  <6   32       22 21  

*P<0.005, **all P<0.001, ***P<0.001 without No CRPC vs. ≥12

PADT: primary androgen deprivation therapy.

CRPC: castration resistant prostate cancer.